Over the last 7 days, the United States market has risen by 7.1%, with a 12-month increase of 7.7% and earnings forecasted to grow by 14% annually. In light of these conditions, investors may find value in exploring stocks that combine strong financial health with growth potential, even within the niche category of penny stocks. Although considered somewhat outdated, penny stocks still represent an intriguing segment for those interested in smaller or newer companies that might offer stability and upside potential when backed by sound balance sheets.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Safe Bulkers (NYSE:SB) | $3.38 | $355.42M | ✅ 4 ⚠️ 3 View Analysis > |
| Tuya (NYSE:TUYA) | $2.22 | $1.2B | ✅ 3 ⚠️ 3 View Analysis > |
| Smith Micro Software (NasdaqCM:SMSI) | $1.12 | $20.8M | ✅ 4 ⚠️ 4 View Analysis > |
| Kiora Pharmaceuticals (NasdaqCM:KPRX) | $3.30 | $9.6M | ✅ 4 ⚠️ 1 View Analysis > |
| Flexible Solutions International (NYSEAM:FSI) | $3.86 | $48.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Waterdrop (NYSE:WDH) | $1.30 | $462.96M | ✅ 4 ⚠️ 0 View Analysis > |
| TETRA Technologies (NYSE:TTI) | $2.71 | $356.14M | ✅ 5 ⚠️ 2 View Analysis > |
| BAB (OTCPK:BABB) | $0.82175 | $5.88M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (NasdaqGS:LCUT) | $3.42 | $79.56M | ✅ 3 ⚠️ 2 View Analysis > |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.7108 | $64.15M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 759 stocks from our US Penny Stocks screener.
We'll examine a selection from our screener results.
Regulus Therapeutics (NasdaqCM:RGLS)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing microRNA-targeting drugs for various diseases in the United States, with a market cap of $182.83 million.
Operations: Regulus Therapeutics does not report any revenue segments.
Market Cap: $182.83M
Regulus Therapeutics, with a market cap of US$182.83 million, is a pre-revenue biopharmaceutical company focused on microRNA-targeting drugs. Despite having no significant revenue streams and being unprofitable, the company remains debt-free and has sufficient cash runway for over a year. Recent positive clinical updates from its ADPKD program indicate potential progress in drug development, though an auditor's report expressed doubts about its ability to continue as a going concern. The stock has experienced high volatility recently, which is common among penny stocks in the biotech sector.
- Get an in-depth perspective on Regulus Therapeutics' performance by reading our balance sheet health report here.
- Evaluate Regulus Therapeutics' prospects by accessing our earnings growth report.
SOPHiA GENETICS (NasdaqGS:SOPH)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: SOPHiA GENETICS SA is a cloud-native software technology company in the healthcare sector with a market cap of $211.19 million.
Operations: The company's revenue is primarily derived from its healthcare software segment, which generated $65.17 million.
Market Cap: $211.19M
SOPHiA GENETICS, with a market cap of US$211.19 million, is focused on healthcare software and reported revenue of US$65.17 million for the full year 2024. Despite being unprofitable with increasing losses over the past five years, the company maintains more cash than its total debt and has a sufficient cash runway for over a year. A recent strategic partnership with Precision for Medicine aims to enhance biomarker discovery and precision medicine services using SOPHiA's AI-driven platform, potentially accelerating clinical trial capabilities in oncology and genetic disorders. The stock remains highly volatile yet undiluted over the past year.
- Click here to discover the nuances of SOPHiA GENETICS with our detailed analytical financial health report.
- Learn about SOPHiA GENETICS' future growth trajectory here.
trivago (NasdaqGS:TRVG)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: trivago N.V. operates a global hotel and accommodation search platform with a market cap of approximately $255.92 million.
Operations: The company's revenue is primarily derived from three geographical segments: Developed Europe (€192.05 million), Americas (€173.64 million), and Rest of World (€90.48 million).
Market Cap: $255.92M
trivago N.V., with a market cap of approximately $255.92 million, operates a global hotel search platform. Despite being unprofitable, it has reduced losses by 4.8% annually over the past five years and maintains a strong balance sheet, with short-term assets (€190.3M) exceeding both short and long-term liabilities. The company is debt-free and trades at 54% below its estimated fair value, though its share price has been highly volatile recently. A recent CFO change may bring new strategic directions as Dr. Wolf Schmuhl assumes the role in June 2025 amidst ongoing efforts to stabilize growth amid industry headwinds.
- Click here and access our complete financial health analysis report to understand the dynamics of trivago.
- Examine trivago's earnings growth report to understand how analysts expect it to perform.
Turning Ideas Into Actions
- Discover the full array of 759 US Penny Stocks right here.
- Want To Explore Some Alternatives? Rare earth metals are the new gold rush. Find out which 23 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Regulus Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com